Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| BPC-157 (Oral Stable Form) | Semax | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 250-500 mcg twice daily via oral capsule on empty stomach. | Research indicates 200-600 mcg daily via intranasal administration (0.1% solution, 2-3 drops per nostril). |
| Timing | On empty stomach, 30 minutes before meals. Twice daily dosing (morning and evening) provides consistent levels. | Morning and early afternoon dosing (avoid evening — may cause stimulation/insomnia). Intranasal preferred for rapid CNS delivery. |
| Cycle Duration | 4-12 weeks. Oral form enables easier long-term use compared to injectable. | 10-14 day cycles with equal rest periods. Some protocols use 3-5 day on / 2 day off patterns. |
| Evidence Level | animal_plus_anecdotal | moderate_human |
Oral-stable BPC-157, typically formulated as the arginate salt, retains the same mechanism as standard BPC-157 — promoting angiogenesis via VEGFR2/PI3K/Akt/eNOS and Src-Caveolin-1-eNOS pathways, enhancing nitric oxide production, and stimulating tendon fibroblast growth and collagen formation. The arginate salt provides a protective buffer against gastric acid degradation, maintaining peptide integrity across a wider pH range. BPC-157 demonstrates remarkable native stability in human gastric juice (24+ hours), and the arginate form reportedly achieves 7-fold greater oral bioavailability compared to the acetate salt in preclinical studies.
Research indicates 250-500 mcg twice daily via oral capsule on empty stomach.
On empty stomach, 30 minutes before meals. Twice daily dosing (morning and evening) provides consistent levels.
4-12 weeks. Oral form enables easier long-term use compared to injectable.
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analog of the ACTH(4-10) fragment that rapidly upregulates brain-derived neurotrophic factor (BDNF) and its signaling receptor TrkB in the hippocampus (1.4-fold BDNF protein increase, 3-fold exon III BDNF mRNA increase). It activates dopaminergic and serotonergic brain systems, enhances neurotrophin gene expression (BDNF, NGF), and modulates intracellular calcium dynamics in brain neurons. Semax lacks ACTH's corticotropic activity, acting purely as a nootropic/neuroprotective agent.
Research indicates 200-600 mcg daily via intranasal administration (0.1% solution, 2-3 drops per nostril).
Morning and early afternoon dosing (avoid evening — may cause stimulation/insomnia). Intranasal preferred for rapid CNS delivery.
10-14 day cycles with equal rest periods. Some protocols use 3-5 day on / 2 day off patterns.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →